Compare · EBS vs NVO
EBS vs NVO
Side-by-side comparison of Emergent BioSolutions Inc. (EBS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EBS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 566.0x EBS ($393.7M).
- Over the past year, EBS is up 9.9% and NVO is down 21.8% - EBS leads by 31.7 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for EBS).
- NVO has more recent analyst coverage (25 ratings vs 14 for EBS).
- Company
- Emergent BioSolutions Inc.
- Novo Nordisk A/S
- Price
- $7.63-0.78%
- $50.31-2.25%
- Market cap
- $393.7M
- $222.81B
- 1M return
- -1.29%
- +15.47%
- 1Y return
- +9.87%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2006
- News (4w)
- 3
- 5
- Recent ratings
- 14
- 25
Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EBS
- SVP, Products Business Williams Paul Anthony sold $25,200 worth of shares (3,000 units at $8.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 159,098 units (SEC Form 4)
- Emergent BioSolutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
- SVP, Products Business Williams Paul Anthony covered exercise/tax liability with 694 shares, decreasing direct ownership by 0.43% to 162,098 units (SEC Form 4)
- EVP, Chief Financial Officer Lindahl Richard S covered exercise/tax liability with 3,964 shares, decreasing direct ownership by 1% to 374,083 units (SEC Form 4)
- EVP, Quality & Ethics, and CPL Glessner Coleen covered exercise/tax liability with 2,018 shares, decreasing direct ownership by 0.99% to 202,201 units (SEC Form 4)
- SVP, Bioservices Hartzel William covered exercise/tax liability with 1,741 shares, decreasing direct ownership by 0.93% to 185,558 units (SEC Form 4)
- Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
- Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
- Emergent BioSolutions to Participate in Upcoming Investor Conferences
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S